PORT HALLOWAY, Cascadia — Vitralis Biotech today announced a $180 million Series C financing led by Halcyon Ridge Capital, with participation from Northfen Ventures and Lanternway Partners.
Proceeds will expand the Kestrel Bay pilot plant and advance VitraGraft toward first-in-human studies.
“Biology is finally becoming an engineering discipline,” said Dr. Maren Okonkwo-Lindqvist, CEO and co-founder.
Media contact: press@vitralis.example · +1 (555) 010-0150